Conditioning regimens and GVHD prophylaxis
. | Standard myeloablative conditioning . | Reduced-intensity conditioning . |
|---|---|---|
| Conditioning regimens, no. (%)* | ||
| Standard myeloablative conditioning | 621 | — |
| TBI-based + cyclophosphamide/others | 273 (44) | — |
| Chemotherapy only | 348 (56) | — |
| Busulphan-cyclophosphamide | 212 (34) | — |
| Busulphan-cyclophosphamide + other(s) | 136 (22) | — |
| Reduced-intensity conditioning | — | 215 |
| Fludarabine + single alkylating agent | — | 96 (45) |
| Fludarabine + busulphan | — | 61 |
| Fludarabine + melphalan | — | 14 |
| Fludarabine + other | — | 21 |
| Fludarabine + low-dose TBI (0.2 Gy) | — | 13 (6) |
| Fludarabine + other agents (except single alkylating agent) | — | 106 (49) |
| Alemtuzumab or ATG-containing | 32 (5) | 50 (23) |
| None or not specified | 589 (95) | 165 (77) |
| GVHD prophylaxis (excluding alemtuzumab or ATG), no. (%)† | ||
| Non-T-cell depletion | 439 (70.7) | 180 (84) |
| CsA + MTX | 356 (57.3) | 71 (33) |
| CsA alone | 22 (3.5) | 69 (32.1) |
| CsA + other drugs (non-MTX) | 61 (9.8) | 40 (18.6) |
| In vitro T-cell depletion + CsA (± MTX) | 138 (22.2) | 10 (4.7) |
| Not detailed | 44 (7.1) | 25 (11.6) |
. | Standard myeloablative conditioning . | Reduced-intensity conditioning . |
|---|---|---|
| Conditioning regimens, no. (%)* | ||
| Standard myeloablative conditioning | 621 | — |
| TBI-based + cyclophosphamide/others | 273 (44) | — |
| Chemotherapy only | 348 (56) | — |
| Busulphan-cyclophosphamide | 212 (34) | — |
| Busulphan-cyclophosphamide + other(s) | 136 (22) | — |
| Reduced-intensity conditioning | — | 215 |
| Fludarabine + single alkylating agent | — | 96 (45) |
| Fludarabine + busulphan | — | 61 |
| Fludarabine + melphalan | — | 14 |
| Fludarabine + other | — | 21 |
| Fludarabine + low-dose TBI (0.2 Gy) | — | 13 (6) |
| Fludarabine + other agents (except single alkylating agent) | — | 106 (49) |
| Alemtuzumab or ATG-containing | 32 (5) | 50 (23) |
| None or not specified | 589 (95) | 165 (77) |
| GVHD prophylaxis (excluding alemtuzumab or ATG), no. (%)† | ||
| Non-T-cell depletion | 439 (70.7) | 180 (84) |
| CsA + MTX | 356 (57.3) | 71 (33) |
| CsA alone | 22 (3.5) | 69 (32.1) |
| CsA + other drugs (non-MTX) | 61 (9.8) | 40 (18.6) |
| In vitro T-cell depletion + CsA (± MTX) | 138 (22.2) | 10 (4.7) |
| Not detailed | 44 (7.1) | 25 (11.6) |